Pricing Log in Create free account
Friday 16 October 2026 Export GLSI’s income statement to Excel — free account

Greenwich LifeSciences, Inc.

GLSI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.55 0.77 −5.03%
Market cap
$224.9M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Greenwich LifeSciences, Inc. (GLSI) Business Profile

Updated before January 2025

Company Overview

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapy treatments for breast cancer. Founded in 2006 and headquartered in Stafford, Texas, GLSI focuses on addressing unmet medical needs in oncology, particularly in the prevention of breast cancer recurrence. The company is led by a team of experienced professionals, including its CEO and President, Snehal Patel, who brings extensive expertise in biotechnology, finance, and strategic planning. The leadership team is supported by a board of directors and scientific advisors with deep knowledge in oncology and drug development.

Core Business Segments

GLSI’s primary focus is on immunotherapy solutions for breast cancer. The company’s flagship product candidate is GP2, a novel immunotherapy designed to prevent the recurrence of HER2/neu-positive breast cancer.

GP2 Immunotherapy

GP2 is a peptide-based immunotherapy that works by stimulating the immune system to target HER2/neu-expressing cancer cells. It is administered in combination with an immune adjuvant to enhance its efficacy. GP2 is currently in Phase III clinical trials, where it has shown promising results in reducing the recurrence of breast cancer in patients who have completed standard treatments such as surgery, chemotherapy, and HER2-targeted therapies.

Research and Development

In addition to GP2, GLSI invests heavily in research and development to expand its pipeline of immunotherapy products. The company is exploring the potential of GP2 in other HER2/neu-expressing cancers and is actively investigating new immunotherapy candidates to address other oncology indications.

Business Model

GLSI operates as a clinical-stage biopharmaceutical company, focusing on the development and commercialization of innovative cancer immunotherapies. The company generates revenue primarily through licensing agreements, partnerships, and potential future product sales. GLSI’s business model emphasizes:

  • Clinical Development: Advancing its pipeline of immunotherapy candidates through rigorous clinical trials to ensure safety and efficacy.
  • Strategic Partnerships: Collaborating with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development and commercialization.
  • Intellectual Property: Protecting its proprietary technologies through patents and trademarks to maintain a competitive edge in the market.

Strategic Direction

GLSI is committed to becoming a leader in the field of cancer immunotherapy. The company’s strategic priorities include:

  • Advancing GP2: Completing Phase III clinical trials for GP2 and obtaining regulatory approval for commercialization.
  • Pipeline Expansion: Developing new immunotherapy candidates to address other oncology indications and unmet medical needs.
  • Global Reach: Establishing partnerships and distribution networks to make its products accessible to patients worldwide.
  • Sustainability Goals: Incorporating sustainable practices in its operations, including reducing its environmental footprint and promoting diversity and inclusion within the organization.

Competitive Landscape

GLSI operates in a highly competitive biopharmaceutical industry, where it faces competition from both established companies and emerging startups. Key competitors include:

  • Genentech (a member of the Roche Group): A leader in HER2-targeted therapies, including trastuzumab (Herceptin) and pertuzumab (Perjeta).
  • AstraZeneca: Known for its oncology portfolio, including HER2-targeted therapies such as trastuzumab deruxtecan (Enhertu).
  • Moderna and BioNTech: Companies specializing in mRNA-based immunotherapies and vaccines, which could potentially compete with peptide-based approaches like GP2.

Despite the competition, GLSI differentiates itself through its focus on preventing breast cancer recurrence and its innovative approach to immunotherapy.

Risk Factors

As a clinical-stage biopharmaceutical company, GLSI faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approval for GP2 or other pipeline products.
  • Market Dependence: Reliance on the success of GP2 for future revenue generation.
  • Clinical Trial Risks: Potential challenges in demonstrating the safety and efficacy of its products in clinical trials.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers for the production of clinical trial materials.
  • Competitive Risks: Intense competition from established companies and new entrants in the oncology market.

Recent Developments

GLSI has made significant progress in advancing its clinical pipeline and corporate strategy. Recent developments include:

  • Phase III Clinical Trials: The company has initiated Phase III trials for GP2, with interim results showing promising efficacy in preventing breast cancer recurrence.
  • Partnerships: GLSI has entered into collaborations with leading academic institutions and research organizations to support its clinical development programs.
  • Corporate Milestones: The company has strengthened its leadership team and secured additional funding to support its growth initiatives.

Investment Considerations

Investors considering GLSI should weigh the following strengths and risks:

Strengths

  • Innovative Product Pipeline: GLSI’s focus on immunotherapy for breast cancer recurrence addresses a significant unmet medical need.
  • Promising Clinical Data: Positive interim results from Phase III trials for GP2 demonstrate its potential efficacy.
  • Experienced Leadership: A seasoned management team with expertise in biotechnology and oncology.

Risks

  • Clinical and Regulatory Uncertainty: The success of GP2 and other pipeline products depends on the outcome of clinical trials and regulatory approvals.
  • Market Competition: Intense competition from established players in the oncology market.
  • Financial Risks: As a clinical-stage company, GLSI relies on external funding and may face challenges in securing additional capital.

Conclusion

Greenwich LifeSciences, Inc. is well-positioned to become a leader in the field of cancer immunotherapy, with its innovative approach to preventing breast cancer recurrence. While the company faces significant risks, its promising clinical data, experienced leadership, and strategic focus on addressing unmet medical needs provide a strong foundation for future growth. As GLSI advances its pipeline and expands its global reach, it has the potential to make a meaningful impact on the lives of cancer patients worldwide.